Key facts
- Notable investors include University of Michigan.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Fragmatics
- ·The full record, as it builds
Funding rounds
No funding rounds for Fragmatics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Fragmatics
Developer of computational tools for mass spectrometry-based proteomics designed to support research and analysis in academic and commercial environments. The company's platform builds on research and incorporates widely used algorithms and tools for peptide and protein identification, offering a comprehensive approach that includes a search engine, compatibility with diverse proteomics workflows, and tools for data interpretation and visualization, enabling researchers and industry partners to conduct large-scale and accurate proteomic studies.
- Sector
- Healthcare
- HQ
- Ann Arbor, MI, United States
- Founded
- 2025
- Website
- fragmatics.com/
- Ownership
- Privately Held (backing)
Fragmatics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Fragmatics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Fragmatics in its N-PORT filings yet. We sweep new filings monthly.